<DOC>
	<DOCNO>NCT00005029</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness topotecan treating patient recurrent ovarian epithelial primary peritoneal cancer .</brief_summary>
	<brief_title>Topotecan Treating Patients With Recurrent Ovarian Epithelial Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity topotecan patient recurrent platinum sensitive ovarian epithelial primary peritoneal cancer . II . Determine nature degree toxicity treatment regimen patient . OUTLINE : Patients receive topotecan IV 30 minute day 1-3 . Treatment continue every 3 week absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 22-60 patient accrue study .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent ovarian epithelial primary peritoneal carcinoma Bidimensionally measurable disease ( ascites pleural effusion consider measurable ) Platinum sensitive ( defined treatment free interval follow response platinum great 6 month ) One prior platinum base chemotherapy regimen management primary disease contain carboplatin , cisplatin , another organoplatinum compound require PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least low limit normal Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Other : No active infection require antibiotic No neuropathy great grade 1 Not pregnant Negative pregnancy test Fertile patient must use effective contraception No prior malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic immunologic agent Chemotherapy : See Disease Characteristics Recovered prior chemotherapy Patients prior paclitaxel therapy may receive second regimen include paclitaxel No prior concurrent cytotoxic chemotherapy recurrent persistent disease , include retreatment initial chemotherapy regimens No prior topotecan Endocrine therapy : At least one week since prior hormonal therapy malignant tumor Prior concurrent hormone replacement therapy allow Radiotherapy : No prior concurrent radiotherapy target sit No prior radiotherapy great 25 % bone marrow Recovered prior radiotherapy Surgery : Recovered prior surgery Other : No prior cancer treatment contraindicates study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>